Verified against court and regulatory records · No upfront fees · Your information is never sold
Quick Eligibility Review
Answer one question at a time. This usually takes under 2 minutes.
Check your eligibility — free
Answer 2-3 quick questions to review your potential case.
Free · Confidential · About 2 minutes · A case specialist responds within 1 business day
Your answers are never sold or shared without your consent.
About Mead Johnson, Reckitt, and Enfamil Premature
Mead Johnson Nutrition Company, now operating as a subsidiary of Reckitt (a British consumer goods corporation), manufactures the Enfamil line of infant formulas. Enfamil Premature is the primary NICU-targeted cow's milk-based formula at the center of NEC litigation. Like Similac Special Care, Enfamil Premature is marketed in multiple caloric densities and is designed for the nutritional management of premature infants in the NICU. Mead Johnson has been manufacturing and marketing Enfamil Premature to hospitals and neonatology practices for decades. Reckitt acquired Mead Johnson in 2017 for approximately $16.6 billion, inheriting the NEC litigation exposure along with the business. Other implicated Mead Johnson products include Enfamil Human Milk Fortifier (a bovine-derived product added to breast milk) and Enfamil NeuroPro Premature.
The Science Behind the Enfamil NEC Claims
The same body of peer-reviewed research that implicates cow's milk-based premature formula generally applies equally to Enfamil Premature as to Similac Special Care. The Lucas and Cole Lancet study (1990), the multiple Cochrane Reviews, and the Journal of Pediatrics study by Sullivan et al. (2010) all document elevated NEC risk from cow's milk-based NICU formulas without distinguishing between brand names. Clinical studies of NICUs that switched from formula-based to exclusive human milk-based nutrition protocols have shown dramatic reductions in NEC regardless of which specific cow's milk formula was replaced. Plaintiffs in Enfamil cases additionally rely on internal Mead Johnson documents produced in discovery that demonstrate corporate awareness of NEC research and marketing decisions made despite that awareness.
Major Enfamil Verdicts: A Record of Accountability
Mead Johnson has faced some of the most significant verdicts in the history of mass tort litigation arising from NEC cases. In October 2022, a St. Louis County, Missouri jury awarded $495 million against Mead Johnson in the Gill case — one of the largest personal injury verdicts in Missouri history. In March 2023, a Madison County, Illinois jury awarded $60 million in the Sherrod case. Additional state court verdicts in Texas and Illinois have produced substantial compensatory and punitive damages against Mead Johnson. These verdicts reflect jury findings that Mead Johnson's failure to warn of the NEC risk was not merely negligent but recklessly indifferent to the safety of premature infants. Post-trial proceedings and appellate review are ongoing in the largest verdicts; most observers expect substantial portions to be upheld or negotiated into global resolution.
How Reckitt's Acquisition Affects Litigation
When Reckitt acquired Mead Johnson in 2017, it acquired all of Mead Johnson's legal liabilities, including NEC litigation exposure. Reckitt is a publicly traded company with significant financial resources, and it has been managing NEC litigation through Mead Johnson as a defendant. Reckitt's annual reports beginning in 2022 began disclosing NEC litigation as a material contingent liability. For families pursuing Enfamil NEC claims, Mead Johnson/Reckitt's financial capacity to pay judgments or settlements is not in question. The litigation will proceed with Mead Johnson & Company, LLC as the named defendant, with Reckitt as the ultimate corporate parent.
Key data
Data & Statistics
$495 million
St. Louis County Circuit Court
$60 million
Madison County Circuit Court
FAQ
Frequently Asked Questions
Dive deeper
Related Guides
- NEC Disease Overview: Stages, Symptoms, and What Happens in the NICUNecrotizing Enterocolitis is a staged disease. Early detection (Stage I) allows medical management; advanced NEC (Stage III) requires emergency bowel surgery with a mortality rate of 20-30%. Understanding the stages, warning signs, and typical NICU progression is essential for families trying to understand what happened to their baby and whether they have a legal claim.
- NEC Evidence and Records: What to Gather and Why It MattersBuilding a successful NEC formula case requires three categories of records: (1) NICU feeding logs documenting formula product and volume; (2) diagnostic records confirming the NEC diagnosis; and (3) long-term medical records documenting the lasting harm. You do not need these records before contacting an attorney — your attorney can obtain them for you — but understanding what is needed helps families gather and preserve evidence.
- NEC Statute of Limitations: State-by-State Deadlines and Minor Tolling RulesThe statute of limitations for NEC formula cases is among the most nuanced in all of mass tort law. Most states toll the SOL for personal injury claims belonging to minor children until the child turns 18 — meaning surviving NEC children often have claims that will not expire for many years. Parents filing their own claims (wrongful death or loss of consortium) face shorter deadlines. Do not assume your claim is time-barred without consulting a NEC attorney.
- NEC Formula Settlements and Verdicts: What Cases Have Resolved and For How MuchNEC formula cases have produced some of the most significant verdicts in the history of mass tort litigation, with individual jury awards ranging from $1.5 million to $495 million. MDL bellwether trials are actively shaping settlement values in 2025-2026. Understanding the landscape of resolved cases helps families calibrate the potential value of their own claims.
- Similac NEC Lawsuit: Abbott Laboratories and Similac Special Care FormulaAbbott Laboratories manufactures Similac Special Care — the most widely used cow's milk-based premature infant formula in the United States. Abbott has faced thousands of NEC lawsuits across state and federal courts, with bellwether verdicts in MDL 3026 producing nine-figure jury awards. Families whose premature infants developed NEC after receiving Similac in the NICU may have viable product liability claims against Abbott.
- Why Premature Infants Are Uniquely Vulnerable to NECThe extreme vulnerability of premature infants to NEC is not an unfortunate coincidence — it is a biological certainty rooted in the profound immaturity of the preterm gut. Understanding why preterm infants are uniquely at risk helps families understand both the medical reality of what happened to their baby and why the NEC risk associated with cow's milk formula should have been disclosed more clearly.
- Breast Milk vs. Formula and NEC: AAP Guidelines and the Donor Milk AlternativeThe American Academy of Pediatrics, the World Health Organization, and the Human Milk Banking Association of North America all recommend pasteurized donor breast milk — not cow's milk-based formula — as the preferred alternative when a mother's own milk is unavailable for premature infants. The failure of Abbott and Mead Johnson to acknowledge this guidance in their marketing to NICUs is central to the NEC litigation.
- NEC MDL 3026 in the Northern District of Illinois: What Families Need to KnowMDL No. 3026 — In Re: Abbott Laboratories, et al., Preterm Infant Formula Products Liability Litigation — is pending before Chief Judge Rebecca R. Pallmeyer in the United States District Court for the Northern District of Illinois. Understanding how the MDL works, what the bellwether trial program has produced, and how your individual case fits into the larger litigation is essential for families considering filing a NEC formula claim.
- NEC Wrongful Death Claims: When a Premature Baby Does Not SurviveLosing a premature baby to NEC is an unimaginable tragedy. Families who lost their infants after NEC developed following formula feeding in the NICU may have wrongful death claims against Abbott and Mead Johnson. These cases carry some of the highest verdicts in the NEC litigation — including nine-figure jury awards — because juries respond powerfully to the preventable death of a premature baby.
- NEC Long-Term Disabilities: Short Bowel Syndrome, TPN, and Neurodevelopmental HarmSurviving NEC is only the beginning of a long medical journey for many premature infants. Short Bowel Syndrome, TPN dependency, intestinal failure-associated liver disease, and neurodevelopmental disabilities including cerebral palsy and cognitive impairment are common long-term sequelae of NEC. These lifelong medical needs dramatically increase the damages available in surviving-infant NEC claims.
- NEC Hospital Liability: Can the NICU or Hospital Also Be Held Responsible?In addition to product liability claims against Abbott and Mead Johnson, some NEC families may have medical malpractice claims against the hospital or NICU if the medical team deviated from the standard of care by failing to follow evidence-based breast milk guidelines, failing to inform parents of the NEC risk of formula, or failing to timely diagnose and treat NEC once it developed.
The full investigation